Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327662 | 1.00 | TOP2A (0.35) | TOP2AEHMT2 | |
| SCHEMBL3327649 | 0.77 | TOP2A (0.38) | TOP2A | |
| SCHEMBL13299035 | 0.77 | TOP2A (0.36) | TOP2AEHMT2 | |
| SCHEMBL13299013 | 0.77 | TOP2A (0.36) | TOP2AEHMT2 | |
| SCHEMBL3327446 | 0.73 | ATM (0.39) | TOP2A | |
| SCHEMBL3327451 | 0.73 | ATM (0.39) | TOP2A | |
| SCHEMBL13850673 | 0.71 | TOP2A (0.33) | TOP2A | |
| SCHEMBL4148786 | 0.71 | TOP2A (0.35) | TOP2A | |
| SCHEMBL13299033 | 0.71 | EPHX2 (0.41) | TOP2A | |
| SCHEMBL13850674 | 0.71 | EPHX2 (0.41) | TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137397-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137397-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | BIRCH ALAN MARTIN | 2009-05-14 | — | — | US | disclosed |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | BIRCH ALAN MARTIN | 2009-05-14 | — | — | US | disclosed |
| EP-1658067-B1 | INDOLAMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1658069-B1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080064691-A1 | Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064691-A1 | Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20060211760-A1 | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211760-A1 | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity | PYGL, PYGM, PYGB | TOP2A 988/4885EHMT2 2265/4885 |
| US-20100137397-A1 | Chemical Compounds | PYGL, PYGM, GYS2 | TOP2A 2308/4885EHMT2 3927/4885 |
| US-20080064691-A1 | Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity | PYGL, PYGM, GYS1 | TOP2A 1987/4885EHMT2 1909/4885 |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | PYGL, PYGM, GYS1 | TOP2A 951/4885EHMT2 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.